Vir Biotechnology Inc (VIR)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -628,194 | 754,280 | 549,802 | -298,611 | -174,529 |
| Revenue | US$ in thousands | 86,180 | 1,615,800 | 1,095,420 | 76,368 | 8,091 |
| Pretax margin | -728.93% | 46.68% | 50.19% | -391.02% | -2,157.08% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-628,194K ÷ $86,180K
= -728.93%
The pretax margin of Vir Biotechnology Inc has exhibited significant fluctuations over the past five years. In 2023, the company reported a negative pretax margin of -728.93%, indicating that its operating expenses and charges exceeded its gross profit, leading to a loss before taxes. This sharp decline from the previous year's pretax margin of 46.68% implies a substantial deterioration in the company's financial performance.
In contrast, 2021 and 2022 saw positive pretax margins of 50.19% and 46.68%, respectively, reflecting healthy profitability levels where the company generated significant earnings before taxes. However, the pretax margin in 2020 was notably negative at -391.02%, suggestive of a period of financial difficulty or inefficiency in cost management.
The most extreme pretax margin was observed in 2019 at -2,157.08%, indicating a substantial loss before taxes that year. This exceptionally large negative margin could be attributed to various factors such as exceptional charges, write-offs, or significant one-time expenses impacting the company's bottom line.
Overall, the data showcases a fluctuating trend in Vir Biotechnology Inc's pretax margin, underlining the company's changing financial performance and operational efficiency over the past five years.
Peer comparison
Dec 31, 2023